induc
csa
associ
appear
antiiaspecif
killer
cell
capabl
lyse
appropri
target
cell
sever
strain
rat
includ
self
lewi
rtlt
aci
rti
bn
rti
femal
rat
corona
virusfre
wk
old
purchas
harlan
spragu
dawley
inc
indianapoli
radiat
lewi
rat
irradi
rad
radsmin
dualsourc
vc
small
anim
irradi
atom
energi
canada
ltd
kanata
ontario
canada
marrow
transplant
donor
anim
kill
asphyxi
marrow
femur
tibia
humeri
collect
hank
solut
supplement
uml
penicillin
gml
streptomycin
marrow
cell
adjust
concentr
nucleat
cellsmi
ml
infus
recipi
anim
intraven
inject
tail
vein
irradi
antibiot
rat
receiv
medic
drink
water
supplement
bactrim
neomycin
polymixin
b
given
mgd
gentamycin
subcutan
previous
describ
cyclosporin
csa
gener
gift
sandoz
ltd
basel
switzerland
powder
csa
dissolv
ethanol
ad
solut
deioniz
ho
rat
weigh
daili
receiv
gd
subcutan
day
marrow
infus
consecut
day
total
dose
csa
per
day
per
rat
mgkg
control
anim
receiv
ident
quantiti
drug
diluent
ethanol
without
csa
assess
gvhd
rat
examin
daili
sign
clinic
gvhd
red
ear
dermat
diarrhea
skin
biopsi
taken
frequent
interv
previous
describ
criteria
use
histolog
document
gvhd
grade
acut
gvh
defin
presenc
lymphocyt
exocytosi
epiderm
destruct
vascular
chang
basal
layer
dyskeratot
cell
andor
lymphocyt
dermal
andor
epiderm
infiltr
anim
sacrif
assess
cellular
immun
reactiv
autopsi
perform
skin
tongu
liver
intestin
spleen
histolog
examin
presenc
gvhd
variou
time
marrow
transplant
cellmedi
lympholysi
assay
cml
cml
assay
perform
use
standard
techniqu
previous
describ
briefli
spleen
ceil
test
anim
fraction
nylon
wool
enrich
cell
use
effector
cell
cml
assay
target
cell
either
phytohemagglutinin
pha
induc
blast
cell
concanavalin
con
induc
blast
cell
label
cr
maximum
spontan
lcr
releas
obtain
ad
ml
n
hci
ml
complet
medium
respect
well
contain
target
cell
percent
specif
tcr
releas
calcul
accord
follow
formula
specif
releas
cpm
experiment
cpm
spontan
x
cpm
maximum
cpm
spontan
effectortarget
ratio
instanc
assay
natur
killer
nk
cell
assay
nk
assay
test
rat
perform
previous
describ
briefli
ceil
murin
tumor
cell
line
yac
label
tcr
serv
target
assess
nk
cell
activ
assay
perform
fashion
compar
cml
assay
describ
monoclon
antibodi
mab
murin
mab
direct
rat
lymphocyt
determin
purchas
sera
lab
accur
chemic
scientif
corp
westburi
ny
specif
mab
ascit
fluid
use
studi
consist
hlk
panspecif
rat
lymphocyt
specif
rat
helper
cell
identifi
rat
nont
helper
cetl
subset
specif
common
determin
class
ii
histocompat
antigen
rat
react
common
class
rat
histocompat
determin
cell
separ
pan
nylon
woolnonadher
spleen
cell
test
anim
separ
lymphocyt
subset
pan
previous
describ
briefli
lymphocyt
incub
h
ml
dilut
phosphatebuff
salin
pb
place
petri
dish
coat
affinitypurifi
goat
antimous
igg
tago
inc
burlingam
ca
plate
lightli
centrifug
g
min
incub
h
nonadher
fraction
aspir
plate
care
wash
pb
adher
fraction
elut
vigor
aspir
solut
normal
mous
serum
control
ascit
fluid
fraction
procedur
routin
achiev
puriti
select
cell
popul
statist
analysi
result
vitro
assay
analyz
statist
signific
student
test
associ
syngen
gvhd
vitro
paramet
cellular
immun
reactiv
perform
x
analysi
initi
studi
undertaken
determin
whether
rat
wtih
syngen
gvhd
syndrom
cytotox
lymphocyt
activ
self
lewi
rat
strain
aci
bn
share
major
histocompat
complex
antigen
lewi
strain
rat
anim
test
variou
interv
cessat
csa
therapi
biopsi
taken
histolog
assess
transplonl
recipi
transplon
recipi
syngenelc
gvhd
without
syngenelc
gvhd
figur
nylon
woolnonadher
spleen
cell
csatreat
syngen
marrow
recipi
without
gvhdlike
syndrom
control
noncsatr
syngen
marrow
recipi
assess
abil
lyse
lewi
aci
bn
pha
con
blast
cell
label
cr
effectortarget
ratio
data
repres
averag
se
activ
anim
five
separ
experi
test
cessat
csa
therapi
gvhd
fig
summar
cytotox
activ
csatreat
syngen
transplant
recipi
gvhd
document
histolog
csatreat
syngen
transplant
recipi
without
evid
gvhd
control
csatreat
syngen
transplant
recipi
data
illustr
nylon
woolnonadher
spleen
cell
csatreat
syngen
transplant
recipi
syngen
gvhd
capabl
mediat
signific
lysi
lewi
aci
bn
target
cell
contrast
csatreat
syngen
transplant
recipi
without
gvhdiik
syndrom
syngen
transplant
recipi
receiv
control
diluent
capabl
mount
signific
lysi
target
cell
rat
receiv
syngen
marrow
transplant
treat
either
control
diluent
csa
follow
cytotox
cell
activ
variou
interv
cessat
csa
therapi
result
present
fig
within
first
withdraw
csa
therapi
anim
exhibit
cytotox
cell
activ
five
anim
show
cytotox
cell
activ
two
anim
evid
clinic
signific
syngen
gvhd
manifest
erythroderma
ear
dermat
diagnosi
confirm
histolog
remain
three
anim
histolog
evid
syngen
gvhd
evid
syngen
gvhd
syndrom
present
five
anim
exhibit
spleen
cellmedi
lysi
test
target
cell
among
anim
test
cessat
csa
therapi
anim
demonstr
cytotox
activ
lewi
aci
bn
blast
cell
anim
clinic
histolog
evid
syngen
gvhd
remain
minim
gvhdlike
histolog
chang
anim
demonstr
signific
spleen
cellmedi
cytotox
activ
two
show
histolog
evid
syngen
gvhd
remain
two
histolog
evid
compat
mild
gvhd
spleen
two
anim
fibrot
limit
cell
recoveri
anim
test
csa
therapi
stop
five
eight
anim
exhibit
cytotox
cell
activ
also
show
histolog
evid
syngen
gvhd
remain
three
anim
exhibit
signific
cytotox
activ
one
show
histolog
evid
syngen
gvhd
anim
treat
csa
follow
syngen
marrow
transplant
exhibit
clinic
andor
histolog
evid
syngen
gvhdiik
syndrom
anim
syndrom
demonstr
cytotox
activ
lewi
aci
andor
bn
target
cell
remain
nine
csatreat
syngen
marrow
recipi
without
syndrom
activ
presenc
cytotox
activ
significantli
p
associ
incid
gvhdiik
syndrom
spleen
cellmedi
cytotox
activ
nontranspl
anim
treat
wtih
csa
nontranspl
anim
treat
control
diluent
assess
regimen
csa
control
diluent
therapi
ident
syngen
marrow
recipi
tabl
demonstr
nylon
woolnonadher
spleen
cell
two
group
capabl
mediat
signific
lysi
aci
lewi
bn
target
cell
tabl
ii
summar
result
nk
activ
four
experiment
group
nk
activ
anim
receiv
syngen
transplant
treat
csa
significantli
p
elev
compar
syngen
marrow
transplant
recipi
treat
csa
anim
receiv
syngen
marrow
transplant
treat
csa
later
exhibit
histolog
evid
syngen
gvh
significantli
differ
n
k
activ
compar
anim
receiv
treatment
show
histolog
sign
gvhd
comparison
nontranspl
anim
receiv
either
control
diluent
csa
level
nk
activ
compar
control
noncsatr
syngen
marrow
recipi
identif
effector
cell
mediat
lysi
attempt
identifi
effector
cell
mediat
lysi
aci
lewi
target
cell
fig
show
result
repres
experi
nylon
woolnonadher
spleen
cell
csatreat
syngen
marrow
transplant
recipi
exhibit
clinic
evid
syngen
gvhd
fraction
distinct
subpopul
recogn
mab
rat
lymphocyt
subset
result
demonstr
deplet
cell
subset
pant
mab
normal
lewi
rat
treat
csa
control
diluent
mgkgd
spleen
cell
anim
harvest
withdraw
csa
therapi
pass
nylon
wool
nonadher
spleen
cell
test
abil
lyse
aci
lewi
bn
blast
cell
effectortarget
ratio
mean
percent
specif
releas
se
remov
spleen
ceilmedi
cytotox
activ
aci
lewi
target
cell
major
activ
recov
adher
fraction
contrast
pan
nylon
woolnonadher
spleen
cell
identifi
rat
helper
cell
result
signific
decreas
activ
rather
result
slight
enhanc
cytotox
activ
aci
lewi
target
cell
cell
adher
fraction
pan
procedur
mediat
signific
lysi
either
target
cell
contrast
remov
cell
repres
rat
nonhelp
cell
subset
result
signific
reduct
cytotox
activ
aci
lewi
target
cell
cytotox
activ
recov
adher
fraction
two
experi
ident
result
observ
minor
except
incomplet
recoveri
cytotox
cell
activ
adher
fraction
cell
pan
pant
mab
seem
like
cell
coat
mab
interf
lysi
suggest
close
associ
antigen
receptor
hypothesi
support
observ
addit
pant
mab
antibodi
cml
assay
result
signific
inhibit
lysi
appear
direct
effector
cell
sinc
preincub
target
pant
mab
result
inhibit
lysi
see
recogn
effector
cell
anim
exhibit
syngen
gvhd
tabl
iii
summar
result
repres
experi
aci
lewi
target
cell
preincub
varieti
mab
use
target
cml
assay
use
effector
cell
anim
syngen
gvhd
syndrom
result
reveal
preincub
lewi
aci
target
cell
antiia
common
determin
mab
result
signific
reduct
lysi
lewi
target
cell
preincub
either
aci
lewi
target
cell
normal
mous
serum
pant
mab
anticlass
antibodi
result
signific
reduct
lysi
three
experi
ident
result
observ
averag
se
reduct
lysi
target
cell
pretreat
lewi
aci
blast
cell
label
incub
normal
mous
serum
mab
ml
dilut
per
cell
h
cell
wash
twice
cold
rpmi
prior
use
target
cml
assay
nylon
wool
nonadber
spleen
anim
syngen
gvhd
syndrom
use
effector
cell
effector
target
ratio
percent
specif
slcr
releas
nt
test
mab
spleen
cell
nylon
woolnonadher
control
transplant
anim
test
mabpretr
target
result
signific
lysi
appar
exclud
fcmediat
lysi
treatment
yac
tumor
cell
antibodi
reduc
nkspecif
lysi
data
shown
confirm
presenc
class
ii
mhc
antigen
activ
rat
lymphocyt
cell
stain
anticlass
ii
antibodi
counterstain
fluorescein
goat
antimous
igg
analyz
fluorescenceactiv
cell
sorter
result
show
pha
con
stimul
rat
ymphoblast
express
class
ii
antigen
activ
antilareact
cell
data
present
demonstr
splenic
cell
rat
syngen
gvhd
capabl
lyse
blast
cell
sever
strain
rat
lysi
mediat
cell
phenotyp
express
antigen
appear
recogn
ia
class
ii
determin
determin
whether
lysi
mediat
one
cell
recogn
multipl
specif
andor
share
determin
whether
polyclon
activ
antiiareact
lymphocyt
seri
cold
targetinhibit
studi
undertaken
fig
give
result
repres
experi
aci
lewi
cold
target
blast
cell
ad
variou
concentr
lytic
assay
use
either
acior
lewislabel
target
result
demonst
aci
lewi
cold
target
equal
effect
inhibit
lysi
ad
cml
assay
label
lewi
target
compar
find
observ
cold
aci
lewi
target
equal
effect
inhibit
lysi
label
aci
target
cell
seri
three
experi
compar
result
observ
signific
differ
cold
aci
lewi
target
cell
abil
inhibit
lysi
hotcold
torget
ratio
f
cure
cold
target
inhibit
studi
perform
use
untabel
aci
andor
lewi
pha
blast
cell
cold
target
ad
grade
quantiti
cml
assay
use
either
scrlabel
aci
lewi
blast
cell
nylon
woolnonadher
spleen
cell
csatreat
syngen
marrow
transplant
recipi
gvhdiik
syndrom
use
effector
cell
effectortarget
ratio
either
lewi
aci
label
target
cell
label
lewi
target
cellscold
aci
target
ratio
inhibit
respect
se
label
lewi
targetscold
lewi
target
ratio
inhibit
respect
label
aci
targetscold
lewi
target
ratio
inhibit
respect
label
aci
targetscold
aci
target
ratio
inhibit
respect
experi
bn
target
cell
also
use
cold
targetinhibitor
found
equal
inhibitori
cold
aci
lewi
target
compar
yac
tumor
cell
ad
cold
targetinhibitor
ineffect
result
support
hypothesi
one
cell
capabl
recogn
aci
lewi
cold
target
polyclon
activ
ofantilareact
ceil
clone
recogn
distinct
specif
cold
targetinhibit
studi
would
reveal
signific
differ
abil
cold
aci
lewi
target
mediat
inhibit
lysi
label
target
studi
confirm
observ
glazier
et
al
csa
treatment
rat
receiv
syngen
marrow
transplant
result
consist
develop
syndrom
indistinguish
gvhd
syndrom
may
gener
autoimmun
phenomena
target
organ
syngen
gvhd
well
histolog
damag
seen
compar
gvhd
follow
ailogen
bone
marrow
transplant
exist
syngen
gvhd
provid
compel
evid
histocompat
differ
absolut
requir
develop
syndrom
one
hypothesi
account
develop
syngen
gvhd
failur
immun
system
discrimin
self
nonself
result
gener
autoreact
ceil
howev
presenc
autoreact
may
normal
process
regul
circumst
syngen
marrow
transplant
subsequ
csa
immunosuppress
regulatori
process
may
alter
result
studi
demonstr
develop
cytotox
cell
recogn
self
class
ii
ia
histocompat
antigen
associ
develop
syngen
gvhdlike
syndrom
perplex
observ
effector
cell
associ
syngen
gvhd
capabl
lyse
blast
cell
sever
strain
rat
appar
unrestrict
fashion
strain
use
share
class
ii
antigen
distinct
atlotyp
respect
class
class
ii
histocompat
antigen
two
hypothes
formul
account
result
polyclon
activ
class
iireact
cell
includ
autoreact
cell
develop
cytotox
effector
cell
appar
multipl
specif
privat
antigen
epitop
cold
targetinhibit
studi
support
latter
hypothesi
sinc
aci
lewi
cold
target
equal
effect
inhibit
lysi
either
aci
lewi
label
target
cell
although
crossreact
within
rat
class
ii
determin
total
exclud
anoth
hypothesi
effector
cell
recogn
common
determin
public
epitop
class
ii
relat
antigen
share
mani
strain
rat
hypothesi
merit
sinc
crossreact
among
rat
major
histocompat
antigen
report
includ
antigen
similar
b
chain
class
ii
molecul
independ
rat
haplotyp
howev
splenic
lymphocyt
rat
syngen
gvhdiik
syndrom
major
instanc
mediat
equival
level
lysi
regardless
target
cell
use
aci
bn
lewi
crossreact
sole
respons
result
would
seem
like
would
differ
abil
effector
cell
lyse
differ
target
studi
need
clarifi
issu
effector
cell
studi
shown
lymphocyt
phenotyp
marker
nont
helper
cell
rat
data
compat
observ
glazier
et
al
cheney
sprent
demonstr
syngen
gvhdlike
syndrom
could
adopt
transfer
irradi
syngen
recipi
although
highli
signific
associ
syngen
gvhd
develop
antiiaspecif
cytotox
cell
remain
unknown
whether
cell
mediat
syndrom
requir
interact
cellsubset
studi
current
underway
adopt
transfer
syngen
gvhd
transfer
cell
popul
enrich
killer
cell
studi
cheney
sprent
use
murin
model
csainduc
syngen
gvhd
strike
decreas
overal
thymic
ia
express
observ
compar
control
transplant
anim
result
studi
could
explain
find
antiia
cytotox
cell
elimin
cell
bear
class
ii
antigen
may
also
syngen
gvhd
reduc
thymic
ia
express
result
failur
lymphocyt
matur
subsequ
induct
specif
cytotox
cell
mechan
csa
lead
syngen
gvhd
allow
develop
polycion
selfantiiareact
cell
remain
unknown
integr
thymic
tissu
appear
critic
factor
import
thymu
induct
syngen
gvhd
support
result
glazier
et
ai
despit
compar
csa
therapi
syngen
gvhd
could
induc
thymu
shield
irradi
contrast
consist
develop
gvhd
seen
csatreat
rat
given
total
bodi
irradi
without
shield
thymu
develop
syngen
gvhd
limit
csatreat
anim
sinc
van
bekkum
devri
describ
develop
syndrom
similar
syngen
autolog
gvhd
neonat
thymectom
anim
anim
receiv
addit
irradi
thymu
studi
impli
role
thymic
integr
induct
syngen
gvhd
nontranspl
nonirradi
anim
treat
csa
develop
syndrom
antiia
cytotox
cell
found
spite
fact
csa
treatment
transplant
nontranspl
anim
lead
remark
thymic
chang
rapid
deplet
medullari
lymphocyt
tempt
specul
csa
alter
educ
process
accentu
matur
failur
lymphocyt
irradi
thymu
allow
develop
polyclon
selfantiiareact
cell
whether
radiat
damag
thymu
deplet
normal
thymocyt
combin
csa
therapi
lead
directli
develop
polyclon
selfclass
iireact
cytotox
cell
develop
syngen
gvhd
remain
unknown
remain
possibl
gener
class
iireact
cytotox
cell
normal
part
ongo
differenti
thymu
control
intrathym
regulatori
event
csa
abat
regulatori
influenc
syngen
gvhd
syndrom
would
appear
radiat
damag
thymu
deplet
normal
thymocyt
includ
regulatori
subset
control
gener
autoreact
cell
regulatori
influenc
host
shown
adopt
transfer
normal
syngen
spleen
cell
spleen
cell
anim
suffer
syngen
gvhd
irradi
lewi
recipi
prevent
develop
syngen
gvhd
howev
transfer
spleen
cell
anim
syngen
gvhd
normal
unirradi
recipi
appar
prevent
develop
syndrom
implic
facet
host
regul
remain
unidentifi
lethal
irradi
rat
reconstitut
syngen
bone
marrow
treat
cyclosporin
csa
develop
graftvshost
diseaselik
syndrom
gvhd
csa
therapi
attempt
assess
develop
autoreact
anim
result
reveal
major
anim
syngen
gvhd
develop
autocytotox
lymphocyt
phenotyp
addit
reactiv
self
cell
capabl
lyse
appropri
target
cell
varieti
differ
rat
strain
target
antigen
appear
class
ii
major
histocompat
antigen
lysi
could
effect
block
antiia
monoclon
antibodi
cold
target
inhibit
studi
indic
one
effector
cell
capabl
lyse
variou
target
cell
provid
evid
polyclon
activ
multipl
antiiareact
cell
result
suggest
anticlass
ii
autoreact
cell
associ
syngen
gvhd
either
recogn
common
class
ii
determin
public
epitop
share
multipl
strain
rat
polyspecif
respect
privat
class
ii
determin
